Pharming Group (PHAR) Projected to Post Quarterly Earnings on Thursday

Pharming Group (NASDAQ:PHAR - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Pharming Group to post earnings of $0.07 per share and revenue of $76.67 million for the quarter.

Pharming Group Stock Performance

PHAR traded down $0.32 during trading on Friday, reaching $8.05. 3,697 shares of the company's stock were exchanged, compared to its average volume of 5,987. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $11.94. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The business has a 50 day moving average price of $9.17 and a 200 day moving average price of $8.57. The company has a market capitalization of $547.65 million, a P/E ratio of -30.96 and a beta of -0.10.

Wall Street Analysts Forecast Growth

PHAR has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Tuesday, December 17th. Jefferies Financial Group initiated coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 target price on the stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.